Royalty Pharma plc

Royalty Pharma buys biopharmaceutical royalties and funds innovations in the US. It acquires and evaluates royalties on various therapies. The company collaborates with innovators from academia, research hospitals, and industry companies. Its portfolio includes royalties on 35 commercial products and 14 development-stage candidates across various therapeutic areas. Founded in 1996, Royalty Pharma is based in New York City.

Overview

Sector

Biotechnology

Target Price

120.9 USD

Current Price

39.2 USD

Potential

209%

Strengths

With an appreciation Potential of 208.76%, based on our fundamental analysis, it suggests the stock may be undervalued.
Price to book ratio (2.51) is lower than the sector mean (24.44).
The company has high returns. ROIC (19.02%) is higher than the sector mean (6.02%).
EV/EBIT (15.52) is lower than the sector mean.
Price to free cash flow (6.31) is lower than the sector mean.
Strong EBITDA Margin of 60.43%.

Weaknesses

The company has high debt. Net Debt to EBITDA Ratio (4.89) is higher than the sector mean.

Indicator	Value
PER	20.3
EV/EBITDA	17.7
Price/Free Cash Flow'	6.3
ROIC	19.0%
Net Debt/EBITDA	4.9

Royalty Pharma plc

Overview

Strengths

Weaknesses

Key Financial Data